Alzheimer’s Disease FDG PET Imaging Pattern in an Amyloid-Negative Mild Cognitive Impairment Subject

Article type: Short Communication

Authors: Tiepolt, Solveig^{a; *} | Patt, Marianne^a | Hoffmann, Karl-Titus^b | Schroeter, Matthias L.^{c; d} | Sabri, Osama^{a; d} | Barthel, Henryk^a

Affiliations: [a] Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany | [b] Department of Neuroradiology, University of Leipzig, Leipzig, Germany | [c] Clinic for Cognitive Neurology and Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany | [d] Research Center for Civilization Diseases, University of Leipzig, Leipzig, Germany

Correspondence: [*] Correspondence to: Solveig Tiepolt, MD, Department of Nuclear Medicine, University of Leipzig, Liebigstr. 18, 04103 Leipzig, Germany. Tel.: +49 341 9718264; Fax: +49 341 9718009; [email protected]

Abstract: The revised NIA-AA diagnostic criteria for Alzheimer’s disease (AD) and mild cognitive impairment (MCI) due to AD make use of amyloid pathology and neurodegeneration biomarkers which increase the diagnostic confidence in the majority of patients. However, in daily praxis, cases with conflicting biomarker constellations occur. A MCI subject underwent neuropsychological testing supplemented by FDG and amyloid PET/MRI as well as CSF sampling. In this subject, the biomarkers of Aβ deposition were negative. [18F]FDG PET, however, showed an AD-typical hypometabolism. Further studies are required to determine frequency and relevance of cases with neurodegeneration-first biomarker constellations to improve our understanding on pathogenesis and diagnosis of AD.

Keywords: Alzheimer’s disease, amyloid, FDG, mild cognitive impairment, PET

DOI: 10.3233/JAD-150163

Journal: Journal of Alzheimer's Disease, vol. 47, no. 3, pp. 539-543, 2015